Literature DB >> 35690668

The impact of body mass index on overall survival in patients with cancer receiving immunotherapy: a dose-response meta-analysis.

Oliver John Kennedy1,2, Marianne Therese Neary3,4.   

Abstract

Entities:  

Year:  2022        PMID： 35690668     DOI： 10.1007/s00262-022-03229-x

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN： 0340-7004            Impact factor:   6.968


× No keyword cloud information.
  6 in total

1.  Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non-Small Cell Lung Cancer.

Authors:  Ganessan Kichenadasse; John O Miners; Arduino A Mangoni; Andrew Rowland; Ashley M Hopkins; Michael J Sorich
Journal:  JAMA Oncol       Date:  2020-04-01       Impact factor: 31.777

2.  The predictive value of body mass index on prognosis and adverse events of cancers treated with immunotherapy: a systematic review and meta-analysis.

Authors:  Yafei You; Chang Jiang; Kunwei Peng; Wenzhuo He; Lei Wang; Yanan Jin; Liangping Xia
Journal:  Cancer Immunol Immunother       Date:  2021-01-29       Impact factor: 6.968

3.  Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis.

Authors:  Jennifer L McQuade; Carrie R Daniel; Kenneth R Hess; Carmen Mak; Daniel Y Wang; Rajat R Rai; John J Park; Lauren E Haydu; Christine Spencer; Matthew Wongchenko; Stephen Lane; Dung-Yang Lee; Mathilde Kaper; Meredith McKean; Kathryn E Beckermann; Samuel M Rubinstein; Isabelle Rooney; Luna Musib; Nageshwar Budha; Jessie Hsu; Theodore S Nowicki; Alexandre Avila; Tomas Haas; Maneka Puligandla; Sandra Lee; Shenying Fang; Jennifer A Wargo; Jeffrey E Gershenwald; Jeffrey E Lee; Patrick Hwu; Paul B Chapman; Jeffrey A Sosman; Dirk Schadendorf; Jean-Jacques Grob; Keith T Flaherty; Dana Walker; Yibing Yan; Edward McKenna; Jeffrey J Legos; Matteo S Carlino; Antoni Ribas; John M Kirkwood; Georgina V Long; Douglas B Johnson; Alexander M Menzies; Michael A Davies
Journal:  Lancet Oncol       Date:  2018-02-12       Impact factor: 41.316

4.  A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable.

Authors:  Alessio Cortellini; Melissa Bersanelli; Sebastiano Buti; Katia Cannita; Daniele Santini; Fabiana Perrone; Raffaele Giusti; Marcello Tiseo; Maria Michiara; Pietro Di Marino; Nicola Tinari; Michele De Tursi; Federica Zoratto; Enzo Veltri; Riccardo Marconcini; Francesco Malorgio; Marco Russano; Cecilia Anesi; Tea Zeppola; Marco Filetti; Paolo Marchetti; Andrea Botticelli; Gian Carlo Antonini Cappellini; Federica De Galitiis; Maria Giuseppa Vitale; Francesca Rastelli; Federica Pergolesi; Rossana Berardi; Silvia Rinaldi; Marianna Tudini; Rosa Rita Silva; Annagrazia Pireddu; Francesco Atzori; Rita Chiari; Biagio Ricciuti; Andrea De Giglio; Daniela Iacono; Alain Gelibter; Mario Alberto Occhipinti; Alessandro Parisi; Giampiero Porzio; Maria Concetta Fargnoli; Paolo Antonio Ascierto; Corrado Ficorella; Clara Natoli
Journal:  J Immunother Cancer       Date:  2019-02-27       Impact factor: 13.751

5.  Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition.

Authors:  Girish S Naik; Sushrut S Waikar; Alistair E W Johnson; Elizabeth I Buchbinder; Rizwan Haq; F Stephen Hodi; Jonathan D Schoenfeld; Patrick A Ott
Journal:  J Immunother Cancer       Date:  2019-03-29       Impact factor: 13.751

6.  BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma.

Authors:  Brian W Labadie; Ping Liu; Riyue Bao; Michael Crist; Ricardo Fernandes; Laura Ferreira; Scott Graupner; Andrew S Poklepovic; Ignacio Duran; Saman Maleki Vareki; Arjun V Balar; Jason J Luke
Journal:  J Transl Med       Date:  2019-11-25       Impact factor: 5.531
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.